Antiarrhythmic therapy: clinical pharmacology update
- PMID: 6384277
- DOI: 10.1002/j.1552-4604.1984.tb01838.x
Antiarrhythmic therapy: clinical pharmacology update
Abstract
Currently available antiarrhythmic agents are limited by side effects and the potential for increasing arrhythmias. In addition, drug interactions, altered disposition of drug as a result of changes in protein binding or concomitant disease processes, active metabolites, and poorly defined therapeutic ranges with great interpatient variability are some of the factors which complicate therapy. An awareness of the possible contribution of these factors in the use of antiarrhythmics is invaluable in both the choice of agent and the establishment of an optimum benefit-to-risk ratio for the patient.
Similar articles
-
Therapeutic monitoring of antiarrhythmic drugs.Ther Drug Monit. 1980;2(2):119-26. doi: 10.1097/00007691-198004000-00002. Ther Drug Monit. 1980. PMID: 6762707 Review.
-
Clinical pharmacology of antiarrhythmic drugs: variability of metabolism and dose requirements.J Cardiovasc Pharmacol. 1991;17 Suppl 6:S74-6. J Cardiovasc Pharmacol. 1991. PMID: 1723123 Review.
-
Pharmacologic causes of arrhythmogenic actions of antiarrhythmic drugs.Am J Cardiol. 1987 Apr 30;59(11):19E-25E. doi: 10.1016/0002-9149(87)90197-4. Am J Cardiol. 1987. PMID: 3554949 Review.
-
Managing geriatric arrhythmias, II: Drug selection and use.Geriatrics. 1991 Apr;46(4):41-4, 49-52, 54. Geriatrics. 1991. PMID: 2010094 Review.
-
Antiarrhythmic agents: drug interactions of clinical significance.Drug Saf. 2000 Dec;23(6):509-32. doi: 10.2165/00002018-200023060-00003. Drug Saf. 2000. PMID: 11144659 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources